Momat Rino nasal spray 50mcg dose 120dose
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Description
Momat Rino Nasal Spray is a clear, thick suspension from white to whitish.
Active ingredients
Mometasone
Release form
Spray
Composition
1 g of the preparation contains the active substance: mometasone furoate monohydrate 0.517 mg (equivalent to mometasone furoate) (0.500 mg), excipients: RC-591 avielsel (microcrystalline cellulose, sodium carmellose), glycerol, citric acid monohydrate, sodium citrate, polysorbate 80, benzalkonium chloride, purified water.
Pharmacological effect
Mometasone furoate is a synthetic corticosteroid for topical use with a pronounced anti-inflammatory effect. The local anti-inflammatory effect of mometasone furoate is manifested in doses that do not cause systemic effects. The mechanism of anti-inflammatory and antiallergic action of mometasone furoate is associated with its ability to reduce the release of mediators of allergic reactions. It is also a potent inhibitor of Th2 cytokine, IL-4 and IL-5 products. Momat Rino Nasal Spray exhibits anti-inflammatory activity during the early and late stages of an allergic reaction.
Pharmacokinetics
The bioavailability of mometasone furoate when used in the form of a nasal spray is very low (<0.1%), and it is practically not detected in the blood plasma, even when using the sensitive method of determination with a sensitivity threshold of 0.25 pg / ml. In vitro binding of mometasone furoate to proteins is 98% - 99%, in the concentration range from 5 to 500 ng / ml. Studies have shown that mometasone furoate is metabolized to several metabolites. No major metabolites were detected in plasma. After incubation in vitro, a minor metabolite of 6β-hydroxymometasone furoate was detected. In human liver microsomes, metabolite formation is regulated by cytochrome P-450 3A4 (CYP3A4). After intravenous administration, the half-life of mometasone furoate from plasma is 5.8 hours. Excreted from the body in the form of metabolites mainly with bile, and to a small extent with urine.
Indications
Seasonal or year-round allergic rhinitis in adults and children over 6 years of age, prevention of moderate to severe allergic rhinitis (recommended 2–4 weeks before the expected start of the flowering season), nasal polyps and related symptoms, including nasal congestion and loss of smell, patients over 18
Contraindications
Hypersensitivity to the components of the drug, the nasal spray should not be used if there is an untreated local infection of the nasal mucosa, because of the inhibitory effect of steroids on wound healing, patients who have recently had nasal surgery or injury should not use the nasal spray in the acute period
Dosage and administration
For nasal application. Before the first use of Momat Rino, a nasal spray, it is necessary to “calibrate” it by pressing the dispensing device 10 times. After the “calibration”, a stereotypical drug supply is established, with each press releasing approximately 100 mg of a suspension containing 50 μg of mometasone furoate (one dose). If a nasal spray has not been used for 14 days or longer, re-calibration is necessary. Before each use, vigorously shake the spray bottle. Seasonal or perennial allergic rhinitis Adults (including elderly patients) and children 12 years and older: the usual recommended dose is two injections (50 micrograms / dose) in each nostril once a day (total dose 200 mcg). After achieving a therapeutic effect for maintenance therapy, it is advisable to reduce the dose to one injection into each nostril 1 time per day (total dose 100 μg). If the reduction of the symptoms of the disease cannot be achieved using the drug at the recommended therapeutic dose, the daily dose can be increased to a maximum of 4 injections in each nostril 1 time per day (total daily dose of 400 micrograms). After reducing the symptoms of the disease, a dose reduction is recommended. Children aged 6 to 11 years: the recommended dose is 1 injection (50 mcg) in each nostril 1 time per day (total daily dose of 100 mcg).
Side effects
Often: irritation at the site of application, burning, itching, sneezing, nasal bleeding, ulcerative changes of the nasal mucosa, headache, pharyngitis. Rarely: shortness of breath, bronchospasm. Very rarely: impaired smell, taste, anaphylactic reactions, angioedema, perforation of the nasal septum.
Overdose
Momat Rino should be used with caution or not used in patients with active or latent tuberculosis infection of the respiratory tract, as well as in untreated fungal, bacterial infection, systemic viral infection, or herpes simplex infection with eye damage.
Interaction with other drugs
When Momat Rino was prescribed, a nasal spray concurrently with loratadine, there was no change in the plasma concentration of loratadine or its main metabolite. Mometasone furoate was not detected in blood plasma using a sensitive determination method with a lower sensitivity threshold of 50 pg / ml.
special instructions
Momat Rino should be used with caution or not used in patients with active or latent tuberculosis infection of the respiratory tract, as well as in untreated fungal, bacterial infection, systemic viral infection, or herpes simplex infection with eye damage.